Lord, Abbett & Co. LLC Aurinia Pharmaceuticals Inc. Transaction History

Lord, Abbett & Co. LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 11, 2021	SELL	$12.3 - $18.73 $5.27 Million - $8.02 Million	-428,363 Closed	0 $0
Q4 2020 Feb 09, 2021	SELL	$12.94 - $16.05 $295,096 - $366,020	-22,805 Reduced 5.05%	428,363 $5.92 Million
Q3 2020 Nov 12, 2020	BUY	$13.19 - $16.66 $1.62 Million - $2.05 Million	122,902 Added 37.44%	451,168 $6.65 Million
Q2 2020 Aug 14, 2020	BUY	$14.12 - $18.33 $96,128 - $124,790	6,808 Added 2.12%	328,266 $5.33 Million
Q1 2020 May 14, 2020	BUY	$11.34 - $21.46 $3.65 Million - $6.9 Million	321,458 New	321,458 $4.67 Million

207

58.3M

914K

1.35M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.18B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.